Companies Dominating the Antibacterial Haemostatic Gels Market
- Pfizer Inc.
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- DEXX Laboratories Inc.
- Medura
- StopBleed
- Zoetis Inc
- Rapid-Seal
- Coloplast Group
- Gel-e-life sciences
- PREVESTDenPro
- Bio-Chem LLC
- Smith & Nephew
- Medtronic
- B. Braun SE
- 3M Company
Browse Key Market Insights with Data Illustration:
In the News
Pfizer Inc. declared that the European Commission (EC) has accepted marketing permission for the organization’s 20-valent pneumococcal conjugate vaccine, sold in the European Union under the brand name PREVENAR 20®, for active vaccination for the hindrance of invasive disease, pneumonia and keen otitis media affected by Streptococcus pneumoniae in toddlers, kids, and adolescents from 6 weeks to lower than 18 years of age.
Pfizer Inc. the transplant organization, declared a leading existence and the fifth successive year as the Distinguished Founder’s Circle Sponsor for the Annual American Society of Transplant Surgeons (ASTS) Winter Symposium organized on January 11 - 14, 2024 in Miami, Florida.
